Jazz Pharmaceuticals Plc (JAZZ)

145.63
NASDAQ : Health Technology
Prev Close 145.63
Day Low/High 0.00 / 0.00
52 Wk Low/High 130.15 / 184.00
Avg Volume 545.50K
Exchange NASDAQ
Shares Outstanding 60.32M
Market Cap 8.64B
EPS 8.10
P/E Ratio 16.91
Div & Yield N.A. (N.A)

Latest News

Jazz Pharmaceuticals Announces Participation At Upcoming Investor Conferences

Jazz Pharmaceuticals Announces Participation At Upcoming Investor Conferences

DUBLIN, Nov. 7, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at four upcoming investor conferences.

Jazz Pharmaceuticals Announces Third Quarter 2018 Financial Results

Jazz Pharmaceuticals Announces Third Quarter 2018 Financial Results

GAAP Diluted EPS of $2.41; Adjusted Diluted EPS of $3.58 Reflects Growth of 11%

Jazz Pharmaceuticals Announces FDA Approval Of Xyrem® (sodium Oxybate) For The Treatment Of Cataplexy Or Excessive Daytime Sleepiness In Pediatric Narcolepsy Patients

Jazz Pharmaceuticals Announces FDA Approval Of Xyrem® (sodium Oxybate) For The Treatment Of Cataplexy Or Excessive Daytime Sleepiness In Pediatric Narcolepsy Patients

This approval of Xyrem by the FDA marks the first medicine approved to treat cataplexy or excessive daytime sleepiness in children and adolescents with narcolepsy ages seven and older

Jazz Pharmaceuticals To Report 2018 Third Quarter Financial Results On November 6, 2018

Jazz Pharmaceuticals To Report 2018 Third Quarter Financial Results On November 6, 2018

DUBLIN, Oct. 23, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2018 third quarter financial results on Tuesday, November 6, 2018, after the close of the financial markets.

Jazz Pharmaceuticals Survey Highlights Significant Impact Of Excessive Daytime Sleepiness Related To Sleep Apnea

Jazz Pharmaceuticals Survey Highlights Significant Impact Of Excessive Daytime Sleepiness Related To Sleep Apnea

Survey respondents reported challenges in their personal, social and professional lives as a result of Excessive Daytime Sleepiness related to sleep apnea

Jazz Pharmaceuticals Announces An Informational Webcast For Investors Related To Vyxeos EU Launch

Jazz Pharmaceuticals Announces An Informational Webcast For Investors Related To Vyxeos EU Launch

DUBLIN, Sept. 11, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast to provide investors with an overview of the AML treatment landscape in the EU as well as a Vyxeos EU launch overview from...

Jazz Pharmaceuticals Announces Participation In Two Upcoming Investor Conferences

Jazz Pharmaceuticals Announces Participation In Two Upcoming Investor Conferences

DUBLIN, Aug. 29, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences.

Vyxeos® Receives Marketing Authorisation In The European Union For Treatment Of Certain Types Of High-Risk Acute Myeloid Leukaemia

Vyxeos® Receives Marketing Authorisation In The European Union For Treatment Of Certain Types Of High-Risk Acute Myeloid Leukaemia

DUBLIN, Aug. 27, 2018 /PRNewswire/ --  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Commission approved Vyxeos ® 44 mg/100 mg powder for concentrate for solution for infusion for the treatment of adults with newly diagnosed,...

Jazz Pharmaceuticals Announces Second Quarter 2018 Financial Results

Jazz Pharmaceuticals Announces Second Quarter 2018 Financial Results

GAAP Diluted EPS of $1.50; Adjusted Diluted EPS of $3.49 Reflects Growth of 36%

Jazz Pharmaceuticals And MD Anderson Cancer Center Collaborate To Evaluate Potential Treatment Options For Hematologic Malignancies

Jazz Pharmaceuticals And MD Anderson Cancer Center Collaborate To Evaluate Potential Treatment Options For Hematologic Malignancies

DUBLIN and HOUSTON, Aug. 6, 2018 /PRNewswire/ --  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and The University of Texas MD Anderson Cancer Center today announced a five-year collaboration agreement with a goal of evaluating therapies for multiple...

CMS Grants New Technology Add-On Payment To Vyxeos® (daunorubicin And Cytarabine) Liposome For Injection

CMS Grants New Technology Add-On Payment To Vyxeos® (daunorubicin And Cytarabine) Liposome For Injection

DUBLIN, Aug. 3, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the United States Centers for Medicare and Medicaid Services (CMS) granted approval for a New Technology Add-on Payment (NTAP) for Vyxeos® (daunorubicin and...

Jazz Pharmaceuticals To Report 2018 Second Quarter Financial Results On August 7, 2018

Jazz Pharmaceuticals To Report 2018 Second Quarter Financial Results On August 7, 2018

DUBLIN, July 24, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2018 second quarter financial results on Tuesday, August 7, 2018, after the close of the financial markets.

Journal Of Clinical Oncology Publishes Pivotal Phase 3 Data For Jazz Pharmaceuticals' Vyxeos® (daunorubicin And Cytarabine) Liposome For Injection

Journal Of Clinical Oncology Publishes Pivotal Phase 3 Data For Jazz Pharmaceuticals' Vyxeos® (daunorubicin And Cytarabine) Liposome For Injection

DUBLIN, July 19, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that data from the pivotal Phase 3 study of Vyxeos® (daunorubicin and cytarabine) liposome for injection compared to standard of care cytarabine and daunorubicin...

Jazz Pharmaceuticals Enters Into Agreement With TerSera Therapeutics LLC For Prialt

Jazz Pharmaceuticals Enters Into Agreement With TerSera Therapeutics LLC For Prialt

DUBLIN, June 29, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a definitive agreement to sell its rights related to Prialt® (ziconotide) intrathecal infusion to TerSera Therapeutics LLC (TerSera) for $80 million in cash at...

Vyxeos™ Receives Positive CHMP Opinion For Treatment Of Certain Types Of High-Risk Acute Myeloid Leukaemia

Vyxeos™ Receives Positive CHMP Opinion For Treatment Of Certain Types Of High-Risk Acute Myeloid Leukaemia

DUBLIN, June 29, 2018 /PRNewswire/ --  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorisation of...

Jazz Pharmaceuticals Announces FDA Acceptance Of Supplemental New Drug Application For Xyrem® (sodium Oxybate) To Treat Cataplexy And Excessive Daytime Sleepiness In Pediatric Narcolepsy Patients

Jazz Pharmaceuticals Announces FDA Acceptance Of Supplemental New Drug Application For Xyrem® (sodium Oxybate) To Treat Cataplexy And Excessive Daytime Sleepiness In Pediatric Narcolepsy Patients

DUBLIN, June 27, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.

Jazz Pharmaceuticals To Present At The Goldman Sachs Global Healthcare Conference

Jazz Pharmaceuticals To Present At The Goldman Sachs Global Healthcare Conference

DUBLIN, June 6, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA.

Jazz Pharmaceuticals Presents Long-Term Safety And Efficacy Data From Phase 3 TONES 5 Study Of Solriamfetol For Excessive Sleepiness In Narcolepsy Or Obstructive Sleep Apnea

Jazz Pharmaceuticals Presents Long-Term Safety And Efficacy Data From Phase 3 TONES 5 Study Of Solriamfetol For Excessive Sleepiness In Narcolepsy Or Obstructive Sleep Apnea

DUBLIN, June 3, 2018 /PRNewswire/ --  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its investigational treatment solriamfetol demonstrated long-term maintenance of efficacy and a tolerable safety profile in the open-label Phase 3 TONES 5...

Jazz Pharmaceuticals Presents Long-Term Safety And Efficacy Data For Xyrem® (sodium Oxybate) In Pediatric Patients With Narcolepsy With Cataplexy

Jazz Pharmaceuticals Presents Long-Term Safety And Efficacy Data For Xyrem® (sodium Oxybate) In Pediatric Patients With Narcolepsy With Cataplexy

DUBLIN, June 3, 2018 /PRNewswire/ --  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Xyrem® (sodium oxybate) oral solution, CIII, demonstrated long-term efficacy for up to one year in reducing cataplexy and excessive daytime sleepiness (EDS)...

New Survey Highlights Lack Of Awareness Of Neurologic Effects Related To Excessive Sleepiness In Patients With Obstructive Sleep Apnea

Survey findings show that while pulmonologists, neurologists and psychiatrists are aware of the negative effects of Excessive Sleepiness (ES) on patients' quality of life, few are familiar with emerging research linking the condition to brain alterations [1],[2]

Why Thousands Will Attend ASH Hematology Conference in Atlanta This Weekend

Why Thousands Will Attend ASH Hematology Conference in Atlanta This Weekend

The FDA approved 11 different hematological treatments this year after approving 11 in the previous two years combined.

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

The firm received a "refusal to file letter" from the FDA regarding the new drug application for Inbrija, a potential treatment for Parkinson's disease.

Jazz Pharmaceuticals And ImmunoGen, Inc. Announce A Strategic Collaboration And Option Agreement To Develop And Commercialize Antibody-Drug Conjugate Products

Jazz Pharmaceuticals And ImmunoGen, Inc. Announce A Strategic Collaboration And Option Agreement To Develop And Commercialize Antibody-Drug Conjugate Products

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and ImmunoGen, Inc. (Nasdaq: IMGN) today announced that the companies have entered into a collaboration and option agreement granting Jazz Pharmaceuticals exclusive, worldwide rights...

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Jazz Shares Lower Amid Notes Offering

The Dublin firm announced an offering of $500 million of exchangeable senior notes due 2024.

Medivation Founder Takes Helm at Axovant, Shares Spike

Medivation Founder Takes Helm at Axovant, Shares Spike

David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.

Trevena, Synergy Lead Biotech Movers

Trevena, Synergy Lead Biotech Movers

Positive phase three data was a boon for Trevena, but Synergy's "Poop Troop" put pressure on its stock.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACSF, CAA, JAZZ, LFL, MTH, SUM, WYNN Downgrades: REV, TROW, WAGE Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix

ChemoCentryx, Jazz Pharmaceuticals, Ionis Pharmaceuticals and Zogenix were among the biotech stock movers in premarket trading Friday.

TheStreet Quant Rating: B (Buy)